IJCS | Volume 33, Nº2, March / April 2020

1. Campos BPS, Gomes GDS, BrazAS, VilelaAT. Cardiovascular Risk Factors and Risk Measurement in Patients with Psoriatic Arthritis in a University Hospital. Int J Cardiovasc Sci. 2020; 33(2):112-118. 2. Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatl Venereol. 2012;26(Suppl 2):3-11 3. Haroon M, Gallagher, P.; Heffernan, E.; FitzGerald, O. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J. Rheumatol. 2014;41(4):1357-65. 4. Boehncke WH, Boehncke S, TobinAM, Kirby B. The ‘psoriatic march’: a econcept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20:303–7. 5. Yamanaka K, Mizutani H. “Inflammatory skin march”: IL-1 mediated skin inflammation, atopic dermatitis, and psoriasis to cardiovascular diseases. J Allergy Clin Immunol. 2015;136(3):823-4 6. Fumian MM, de Motta NA, Maia R, Fraga CA, Barreiro EJ, de Brito FC. LASSBio-1425, an analog of thalidomide, decreases triglyceride and increases HDL cholesterol levels by inhibition of TNF-a production. Int J Cardiol. 2016 Jan 1;202:497-9. 7. Flammer AJ, Ruschitzka F. Psoriasis and atherosclerosis: two plaques, one syndrome? Eur Heart J. 2012;33:1989-91. 8. Furue, M.; Kadono, T. “In ammatory skin march” in atopic dermatitis and psoriasis. In amm Res. 2017;66(10):833-42. 9. Hu SC, Lan CE. Psoriasis and cardiovascular comorbidities: focusing in severe vascular events, cardiovascular risk factors and implications for treatment. Int J Mol Sci 2017;18(10):2211. 10. Su YS, YuHS, Li WC, Ko YC, Chen GS, Wu CS, et al. Psoriasis as initiator or amplifier of the systemic inflammatorymarch: impact on development of severe vascular events and implications for treatment strategy. J Eur Acad Dermatol Venereol. 2013;27(7):876-83. 11. Davidovici BB, Sattar N, Prinz JC, Puiz L, Emery P, Barker JN, et al. Psoriasis and systemic in ammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130(7):1785-96. References 111 Boechat Psoriatic March Int J Cardiovasc Sci. 2020; 33(2):109-111 Editorial This is an open-access article distributed under the terms of the Creative Commons Attribution License